Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Abbas, Ume L ^a   Hood, Gregory ^b   Wetzel, Arthur W ^b   Mellors, John W ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PITTSBURGH SUPERCOMPUTING CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AFRICA; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; PRE EXPOSURE PROPHYLAXIS; PREDICTION; PREVALENCE; PREVENTIVE MEDICINE; PROCESS MODEL; PUBLIC HEALTH SERVICE; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT DURATION; VIRUS TRANSMISSION; DISEASE TRANSMISSION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; UNCERTAINTY; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; UNCERTAINTY;

EID: 79954559071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018165     Document Type: Article

References (46)

1. AIDS Vaccine Advocacy Coalition PrEP watch Available at: http://wwwprepwatchorg/ Accessed: 22 March 2011.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
3. Anderson RM, May RM, (1991) Infectious diseases of humans: dynamics and control Oxford Oxford University Press.
4. Abbas UL, Anderson RM, Mellors JW, (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2: e875.
5. Nowak MA, May R, (2001) Virus dynamics: mathematical principles of immunology and virology New York Oxford University Press.
6. Coffin JM, (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
7. Van Rompay KK, Singh RP, Heneine W, Johnson JA, Montefiori DC, et al. (2006) Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol 80: 6399-6410.
8. Atchison R, Liegler T, Javier J, Fiss E, Hecht F, et al. (2005) Early and isolated reversion of transmitted RT K65R in a multi-drug resistant infection detected using a novel quantitative allele-specific PCR. Antivir Ther 10 (Suppl 1): 45.
9. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, et al. (2005) Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192: 1537-1544.
10. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, et al. (2003) Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37: 1693-1698.
11. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, et al. (2001) Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75: 6410-6417.
12. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, et al. (2004) Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78: 4234-4247.
13. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20: 701-710.
14. García-Lerma JG, Qari S, Otten R, Johnson J, Kim C, et al. (2006) Blunted viraemia and slow drug resistance emergence in rhesus macaques failing chemoprophylaxis with emtricitabine. Antivir Ther 11 (Suppl 1): 52.
15. Weber J, Chakraborty B, Weberova J, Miller MD, Quinones-Mateu ME, (2005) Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 43: 1395-1400.
16. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, et al. (2002) Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 46: 3437-3446.
17. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, et al. (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187: 683-686.
18. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, et al. (2004) Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 37: 1627-1631.
19. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, et al. (2004) Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 9: 375-384.
20. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, et al. (2001) Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15: 2189-2191.
21. Izopet J, Souyris C, Hance A, Sandres-Saune K, Alvarez M, et al. (2002) Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 185: 1506-1510.
22. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
23. Iman RL, Johnson ME, Schroeder TA, (2002) Assessing hurricane effects. Part 1. Sensitivity analysis. Reliab Eng Syst Safe 78: 131-145.
24. Saltelli A, Chan K, Scott EM, eds. (2000) Sensitivity analysis John Wiley & Sons.
25. Iman RL, Johnson ME, Schroeder TA, (2002) Assessing hurricane effects. Part 2. Uncertainty analysis. Reliab Eng Syst Safe 78: 147-155.
26. Iman RL, Conover WJ, (1979) The use of the rank transform in regression. Technometrics 21: 499-509.
27. Grassly NC, Lowndes CM, Rhodes T, Judd A, Renton A, et al. (2003) Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. Int J Drug Policy 14: 25-43.
28. Hofer E, (1999) Sensitivity analysis in the context of uncertainty analysis for computationally intensive models. Comput Phys Commun 117: 21-34.
29. Garnett GP, Anderson RM, (1994) Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J Math Appl Med Biol 11: 161-192.
30. Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W, (2010) Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci 31: 74-81.
31. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.
32. Grant R, Lama J, Goicochea P, Levy V, Porco T, (2006) Cost-effectiveness analysis of HIV chemoprophylaxis [Abstract THLB0102]. XVI International AIDS Conference. Toronto, Canada.
33. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
34. Smith D, Kebaabetswe P, Disasi K, Fleming D, Paxton L, et al. Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach; 2006 Aug 13-18; Toronto, Canada.
35. van de Vijver DA, Derdelinckx I, Boucher CA, (2009) Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. J Infect Dis 199: 1310-1317.
36. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ, (2008) The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE 3: e2077.
37. Supervie V, Garcia-Lerma JG, Heneine W, Blower S, (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 107: 12381-12386.
38. Johnson J, Van Rompay K, Delwart E, Heneine W, (2006) Rapid emergence of drug-resistant SIV in tenofovir-treated macaques: implications for tenofovir chemoprophylaxis against HIV [Abstract 609]. Program and Abstracts of the13th Conference on Retroviruses and Opportunistic Infections Denver, CO.
39. Tedder RS, Kaye S, Loveday C, Weller IV, Jeffries D, et al. (1998) Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol 36: 1056-1063.
40. Brun-Vezinet F, Boucher C, Loveday C, Descamps D, Fauveau V, et al. (1997) HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 350: 983-990.
41. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, et al. (1998) HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol 17: 203-208.
42. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28.
43. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 194: 904-911.
44. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, et al. (2006) High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 50: 4182-4185.
45. Miller MD, Margot N, McColl D, Cheng AK, (2007) K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS 21: 265-266.
46. Miller DK, Homan SM, (1994) Determining transition probabilities: confusion and suggestions. Med Decis Making 14: 52-58.